Session Title: Quick Fire Free Paper Session 04
Session Date/Time: Sunday 29/09/2013 | 11:00-13:00
Paper Time: 11:35
Venue: Hall C (Level 1)
First Author: R.Rosa PORTUGAL
Co Author(s): T. Brito A. Ferreira M. Lisboa M. Marques
Central serous chorioretinopathy is a benign idiopathic condition characterized by a serous detachment of the neurosensory retina in the macular area, secondary to subretinal fluid accumulation caused by choriocapillaris hyperpermeability and retinal pigment epithelium dysfunction. It is generally a self-limited disease with good visual prognosis, although in some cases it may become chronic, requiring treatment. The objective of this study is to evaluate the safety and efficacy of low-fluence photodynamic therapy (LFPDT) with verteporfin in patients with chronic central serous chorioretinopathy (CCSC).
This study was performed by the Medical Retina Department at Centro Hospitalar de Lisboa Central, Portugal.
A retrospective and nonrandomized study was performed on 11 eyes of 10 patients with CCSC treated LFPDT. Best corrected visual acuity (BCVA) with Snellen decimal scale, fundus findings, central foveal thickness (CFT) using optical coherence tomography (OCT), fluorescein angiography and complications of treatment were evaluated as outcomes measures.
11 eyes of 10 patients were studied, 8 men and 2 women with a mean age of 57.5 years (range between 36 and 69 years). The BCVA improved or remained stable in 10 eyes, with vision loss in one eye. The anatomic results were evaluated by fundoscopy and OCT, with complete resolution of neurosensory retina detachment in 10 cases, causing an average reduction in CFT of 216.8 microns. Two eyes underwent 2 treatment sessions for recurrence or persistence of serous detachment, and one of them evolved to cystoid macular edema. There were no systemic complications reported with treatment.
LFPDT can be a safe and effective technique in anatomic and functional treatment of CCSC, resulting in significant improvement or stabilization of BCVA, reduction of CFT and resolution subretinal fluid.